Patents by Inventor Simona M Ceccarelli
Simona M Ceccarelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9809599Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.Type: GrantFiled: November 11, 2015Date of Patent: November 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
-
Patent number: 9708340Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: September 16, 2015Date of Patent: July 18, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Patent number: 9688675Abstract: The present invention relates to compounds of general formula I wherein R1, R2, R3 and R4 are as defined herein which may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.Type: GrantFiled: January 27, 2016Date of Patent: June 27, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Jens-Uwe Peters, Juergen Wichmann
-
Patent number: 9657014Abstract: The present invention relates to the use of compounds of general formula I wherein R?, R1, R2 and R3 are as defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, and for methods to treat a variety of neurodegenerative and neuropsychiatric diseases.Type: GrantFiled: May 20, 2015Date of Patent: May 23, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Jens-Uwe Peters, Juergen Wichmann
-
Patent number: 9604977Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and methods of using the compounds as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors for the treatment or prophylaxis of type 2 diabetes, atherosclerosis, chronic kidney diseases, non-alcoholic steatohepatitis and cancer.Type: GrantFiled: December 18, 2014Date of Patent: March 28, 2017Assignee: Hoffman-La Roche Inc.Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Patent number: 9586903Abstract: The present invention relates to the use of compounds of general formula wherein R1 is phenyl or pyridinyl, which are optionally substituted by halogen, cyano or lower alkyl substituted by halogen, or is dihydro-pyran-4-yl; R2 is hydrogen or lower alkyl; R3 is —(CHR)n-phenyl, optionally substituted by lower alkoxy or S(O)2-lower alkyl, or is heterocycloalkyl, optionally substituted by ?O and lower alkyl, or is —(CH2)n-five or six membered heteroaryl, optionally substituted by lower alkyl, or is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, —NR—S(O)2-lower alkyl, —(CH2)n-cycloalkyl or —(CH2)n—S(O)2-lower alkyl; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl ring, selected from the group consisting of 1,1-dioxo-thiomorpholinyl, morpholinyl, or pyrrolidinyl, optionally substituted by hydroxyl; R is hydrogen or lower alkyl; n is 0, 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixtureType: GrantFiled: October 29, 2015Date of Patent: March 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Juergen Wichmann
-
Patent number: 9440962Abstract: The present invention relates to compounds of general formula wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-.Type: GrantFiled: January 22, 2015Date of Patent: September 13, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Publication number: 20160185795Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: September 16, 2015Publication date: June 30, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
-
Patent number: 9365550Abstract: The present invention relates to compounds of general formula wherein R1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or halogen; X1 is N or CH; X2 is N or CH; with the proviso that only one of X1 or X2 is N; X3 is C(R) or N; and R is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy or SO2-lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: GrantFiled: March 31, 2015Date of Patent: June 14, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Patent number: 9353102Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A, E and n are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: March 11, 2015Date of Patent: May 31, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Publication number: 20160137643Abstract: The present invention relates to compounds of general formula I wherein R1, R2, R3 and R4 are as defined herein which maybe used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.Type: ApplicationFiled: January 27, 2016Publication date: May 19, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Jens-Uwe Peters, Juergen Wichmann
-
Patent number: 9315502Abstract: The present invention relates to compounds of general formula wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(O)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: GrantFiled: May 27, 2015Date of Patent: April 19, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Patent number: 9284321Abstract: The present invention relates to compounds of general formula I or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, R and n are as defined herein. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.Type: GrantFiled: February 4, 2015Date of Patent: March 15, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann
-
Patent number: 9278918Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: GrantFiled: September 17, 2015Date of Patent: March 8, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Bernd Buettelmann, Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Hans Richter
-
Publication number: 20160060270Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.Type: ApplicationFiled: November 11, 2015Publication date: March 3, 2016Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
-
Publication number: 20160046583Abstract: The present invention relates to the use of compounds of general formula wherein R1 is phenyl or pyridinyl, which are optionally substituted by halogen, cyano or lower alkyl substituted by halogen, or is dihydro-pyran-4-yl; R2 is hydrogen or lower alkyl; R3 is —(CHR)n-phenyl, optionally substituted by lower alkoxy or S(O)2-lower alkyl, or is heterocycloalkyl, optionally substituted by ?O and lower alkyl, or is —(CH2)n-five or six membered heteroaryl, optionally substituted by lower alkyl, or is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, —NR—S(O)2-lower alkyl, —(CH2)n-cycloalkyl or —(CH2)n—S(O)2-lower alkyl; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl ring, selected from the group consisting of 1,1-dioxo-thiomorpholinyl, morpholinyl, or pyrrolidinyl, optionally substituted by hydroxyl; R is hydrogen or lower alkyl; n is 0, 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixtureType: ApplicationFiled: October 29, 2015Publication date: February 18, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Juergen Wichmann
-
Publication number: 20160002152Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: September 17, 2015Publication date: January 7, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: BERND BUETTELMANN, SIMONA M. CECCARELLI, AURELIA CONTE, HOLGER KUEHNE, BERND KUHN, WERNER NEIDHART, ULRIKE OBST SANDER, HANS RICHTER
-
Patent number: 9199938Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6 and n are as described herein, compositions including the compounds and methods of using the compounds. The present compounds are useful as fatty-acid binding protein (FABP) 4 and/or 5 inhibitors and may be used for the treatment or prophylaxis of lipodystrophy, type 2 diabetes, dyslipidemia, atherosclerosis, liver diseases involving inflammation, steatosis and/or fibrosis, such as non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, metabolic syndrome, obesity, chronic inflammatory and autoimmune inflammatory diseases.Type: GrantFiled: November 1, 2012Date of Patent: December 1, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: Simona M. Ceccarelli, Aurelia Conte, Holger Kuehne, Bernd Kuhn, Werner Neidhart, Ulrike Obst Sander, Markus Rudolph
-
Patent number: 9139593Abstract: Provided are compounds of Formula I, R1-L1-A-L2-R2??(I), and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein A, L1, L2, R1 and R2 are defined herein. The present invention also provides a pharmaceutical composition and methods of using such compounds. The compounds are useful for therapy and/or prophylaxis in a patient, and in particular to inhibitors of Soluble Epoxide Hydrolase (sEH).Type: GrantFiled: July 10, 2014Date of Patent: September 22, 2015Assignee: HOFFMANN-LA ROCHE INC.Inventors: Simona M. Ceccarelli, Carine Guerot, Henner Knust
-
Publication number: 20150259341Abstract: The present invention relates to compounds of general formula wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(0)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof.Type: ApplicationFiled: May 27, 2015Publication date: September 17, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Juergen Wichmann